The European Commission approved Novo Holdings' acquisition of Catalent, enabling Novo Nordisk to acquire three manufacturing sites from Novo Holdings, with the deal initially announced on February 5, 2024. The completion is expected by the end of 2024, pending further regulatory approvals.